Abstract:Importance: Despite the widespread awareness of functional magnetic resonance imaging findings suggesting a role for cortical connectivity networks in treatment selection for major depressive disorder, its clinical utility remains limited. Recent methodological advances have revealed functional magnetic resonance imaging-like connectivity networks using electroencephalography (EEG), a tool more easily implemented in clinical practice. Objective: To determine whether EEG connectivity could reveal neural moderators of antidepressant treatment. Design, setting, and participants: In this nonprespecified secondary analysis, data were analyzed from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinic Care study, a placebo-controlled, double-blinded randomized clinical trial. Recruitment began July 29, 2011, and was completed December 15, 2015. A random sample of 221 outpatients with depression aged 18 to 65 years who were not taking medication for depression was recruited and assessed at 4 clinical sites. Analysis was performed on an intent-to-treat basis. Statistical analysis was performed from November 16, 2018, to May 23, 2019. Interventions: Patients received either the selective serotonin reuptake inhibitor sertraline hydrochloride or placebo for 8 weeks. Main outcomes and measures: Electroencephalographic orthogonalized power envelope connectivity analyses were applied to resting-state EEG data. Intent-to-treat prediction linear mixed models were used to determine which pretreatment connectivity patterns were associated with response to sertraline vs placebo. The primary clinical outcome was the total score on the 17-item Hamilton Rating Scale for Depression, administered at each study visit. Results: Of the participants recruited, 9 withdrew after first dose owing to reported adverse effects, and 221 participants (150 women; mean [SD] age, 37.8 [12.7] years) underwent EEG recordings and had high-quality pretreatment EEG data. After correction for multiple comparisons, connectome-wide analyses revealed moderation by connections within and between widespread cortical regions-most prominently parietal-for both the antidepressant and placebo groups. Greater alpha-band and lower gamma-band connectivity predicted better placebo outcomes and worse antidepressant outcomes. Lower connectivity levels in these moderating connections were associated with higher levels of anhedonia. Connectivity features that moderate treatment response differentially by treatment group were distinct from connectivity features that change from baseline to 1 week into treatment. The group mean (SD) score on the 17-item Hamilton Rating Scale for Depression was 18.35 (4.58) at baseline and 26.14 (30.37) across all time points. Conclusions and relevance: These findings establish the utility of EEG-based network functional connectivity analyses for differentiating between responses to an antidepressant vs placebo. A role emerged for parietal cortical regions in predicting placebo outcome. From a treatment perspective, capitalizing on the therapeutic components leading to placebo response differentially from antidepressant response should provide an alternative direction toward establishing a placebo signature in clinical trials, thereby enhancing the signal detection in randomized clinical trials. Trial registration: ClinicalTrials.gov identifier: NCT01407094.

Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo

Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment

Predictors of the placebo response in a nutraceutical randomized controlled trial for depression

Novel multi-modal methodology to investigate placebo response in major depressive disorder

Is There a Placebo Problem in Antidepressant Trials?

Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial

An integrated precision medicine approach in major depressive disorder: a study protocol to create a new algorithm for the prediction of treatment response

Meta-Analysis of Placebo Response in Adult Antidepressant Trials

Placebo response in RCT for antidepressant may not always be the 'villain' to fight: are KOR antagonists possibly affecting the intrinsic placebo response?

Effect of pharmacogenomic testing on the clinical treatment of patients with depressive disorder: A randomized clinical trial

Treatment Response Prediction in Major Depressive Disorder Using Multimodal MRI and Clinical Data: Secondary Analysis of a Randomized Clinical Trial

Development and Validation of a Deep-Learning Model for Differential Treatment Benefit Prediction for Adults with Major Depressive Disorder Deployed in the Artificial Intelligence in Depression Medication Enhancement (AIDME) Study

Growing Placebo Response in TMS Treatment for Depression: a Meta-Analysis of 27-Year Randomized Sham-Controlled Trials

Placebo effects in randomized trials of pharmacological and neurostimulation interventions for mental disorders: An umbrella review

Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study

Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis

Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis

Placebo-controlled randomized clinical trials of antidepressants for major depressive disorder: analysis of ClinicalTrials.gov, 2008-2022

Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study

Comparative Efficacy of Placebos in Short-Term Antidepressant Trials for Major Depression: a Secondary Meta-Analysis of Placebo-Controlled Trials

Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring